GeneVav - Model Prime/VesiculoVax - Boost Therapeutic Vaccine for HCV

Program Status:

With support from the National Cancer Institute, the lead vaccine has demonstrated robust, broad, and high quality immune responses in non-human primates. Further development of this candidate is currently on hold and is available for out-licensing or co-development.

Unmet Medical Need:

Overseas, particularly in Asia, HCV disease is projected to cause an unmanageable burden on global health care over the next 10 to 20 years. Unfortunately, the economies of these many of these nations will not support the cost of the newly developed proprietary drugs for treating HCV infection. The Auro Vaccine GeneVax™ prime/VesiculoVax™ boost therapeutic HCV vaccine is designed to be used in conjunction with less costly generic drugs to cure HCV infection.